Malcolm White
@mfwhite2.bsky.social
Molecular microbiologist at the University of St Andrews, Scotland. My scientific interests include: CRISPR, antiviral defence, cyclic nucleotide signalling, archaea, nucleases.
Reposted by Malcolm White
'After assessing the DMC’s recommendations and conducting an internal analysis of unexpectedly high rates of adverse events, the Company has elected to discontinue the trial'
January 16, 2026 at 4:45 PM
'After assessing the DMC’s recommendations and conducting an internal analysis of unexpectedly high rates of adverse events, the Company has elected to discontinue the trial'
The Biochemical Journal offers a rapid decision on your submission and expert academic editors. All proceeds are used to support the academic community. Please get in touch if you'd like to discuss a potential submission!
January 14, 2026 at 12:07 PM
The Biochemical Journal offers a rapid decision on your submission and expert academic editors. All proceeds are used to support the academic community. Please get in touch if you'd like to discuss a potential submission!